These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 11425419)

  • 21. Severe cholestasis and acute renal failure related to rofecoxib.
    Linares P; Vivas S; Jorquera F; Olcoz JL; de Leon B; Oritz de Urbina J
    Am J Gastroenterol; 2004 Aug; 99(8):1622-3. PubMed ID: 15307886
    [No Abstract]   [Full Text] [Related]  

  • 22. [Rofecoxib-related cutaneous vasculitis].
    Defuentes G; Lecoules S; Coutant G; Algayres JP
    Presse Med; 2005 Aug; 34(14):1007-8. PubMed ID: 16225254
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Extreme sinus bradycardia (30/min) with acute right heart failure under tizanidine (Sirdalud). Possible pharmacological interaction with rofecoxib (Vioxx)].
    Kick A; Bertoli R; Moschovitis G; Caduff Janosa P; Cerny A
    Med Klin (Munich); 2005 Apr; 100(4):213-6. PubMed ID: 15834531
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nephrotoxicity with cyclooxygenase 2 inhibitor use in children.
    Fletcher JT; Graf N; Scarman A; Saleh H; Alexander SI
    Pediatr Nephrol; 2006 Dec; 21(12):1893-7. PubMed ID: 16955281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Delirium From the COX-2 inhibitor refecoxib.
    Muralee S; Bober D; Tampi R
    Psychosomatics; 2004; 45(4):361-3. PubMed ID: 15232052
    [No Abstract]   [Full Text] [Related]  

  • 26. [Gynecomastia secondary to rofecoxib].
    Martínez JA; Tejada González P; Gutiérrez Sanpedro N; González Blanco P
    Med Clin (Barc); 2002 Jun; 118(20):798-9. PubMed ID: 12049701
    [No Abstract]   [Full Text] [Related]  

  • 27. [Selective Cox-2 inhibitor in osteoarthritis and rheumatoid arthritis. No increased risk for the heart].
    MMW Fortschr Med; 2003 Mar; 145(11):60. PubMed ID: 12688204
    [No Abstract]   [Full Text] [Related]  

  • 28. [No loss of effectiveness with rofecoxib. Long-term control of rheumatoid pain].
    Einecke D
    MMW Fortschr Med; 2002 Nov; 144(46):68. PubMed ID: 12534087
    [No Abstract]   [Full Text] [Related]  

  • 29. [Calcified].
    Gerber L; Gaspert A; Bleisch JA
    Praxis (Bern 1994); 2012 May; 101(11):739-42. PubMed ID: 22618699
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Safety of specific cyclo-oxygenase 2 inhibitors].
    Lems WF; van de Laar MA; Bijlsma JW
    Ned Tijdschr Geneeskd; 2001 Jun; 145(22):1044-7. PubMed ID: 11414163
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclooxygenase-2 inhibitor-associated acute renal failure: case report with rofecoxib and review of the literature.
    Morales E; Mucksavage JJ
    Pharmacotherapy; 2002 Oct; 22(10):1317-21. PubMed ID: 12389882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. COX-2 inhibitors and acute interstitial nephritis: case report and review of the literature.
    Esteve JB; Launay-Vacher V; Brocheriou I; Grimaldi A; Izzedine H
    Clin Nephrol; 2005 May; 63(5):385-9. PubMed ID: 15909599
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the baseline cardiovascular risk profile among hypertensive patients prescribed COX-2-specific inhibitors or nonspecific NSAIDs: data from real-life practice.
    Zhao SZ; Burke TA; Whelton A; von Allmen H; Henderson SC
    Am J Manag Care; 2002 Oct; 8(15 Suppl):S392-400. PubMed ID: 12416789
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
    Bogaty P; Brophy JM; Noel M; Boyer L; Simard S; Bertrand F; Dagenais GR
    Circulation; 2004 Aug; 110(8):934-9. PubMed ID: 15302800
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rofecoxib does not adversely affect skin graft survival in a rat model.
    Miller Q; Losken A; Harre JG; Bird ME
    Curr Surg; 2004; 61(2):227-30. PubMed ID: 15051270
    [No Abstract]   [Full Text] [Related]  

  • 36. Reversible acute interstitial nephritis associated with indomethacin.
    Green J; Yoffe B; Barzilai D; Better OS
    Isr J Med Sci; 1985 Feb; 21(2):142-5. PubMed ID: 3980192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [COX-2 inhibitor in arthrosis. Discontinuation before operations not necessary].
    MMW Fortschr Med; 2001 Oct; 143(42):64. PubMed ID: 11697296
    [No Abstract]   [Full Text] [Related]  

  • 38. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
    Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
    Ann Allergy Asthma Immunol; 2005 Jan; 94(1):34-8. PubMed ID: 15702813
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk of myocardial infarction associated with selective COX-2 inhibitors: questions remain.
    Jüni P; Dieppe P; Egger M
    Arch Intern Med; 2002 Dec 9-23; 162(22):2639-40; author reply 2640-2. PubMed ID: 12456259
    [No Abstract]   [Full Text] [Related]  

  • 40. [Selective cyclooxygenase-2 inhibitors and the digestive tract].
    Chaabouni H; Amouri A; Cheikh I; Kchaou M; Ouerghi H; Ben Mami N; Ben Ammar A
    Tunis Med; 2002 Aug; 80(8):427-33. PubMed ID: 12703120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.